Understanding the Next Generation of KIT Inhibitors in Indolent Systemic Mastocytosis

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, overviews the phase 3 HARBOR trial evaluating elenestinib in indolent systemic mastocytosis.

Part 2 of the ongoing phase 2/3 HARBOR study is evaluating elenestinib in patients with indolent systemic mastocytosis.

Tsewang Tashi, MD, discusses how elenestinib could be an effective option with a manageable safety profile in ISM.

Tsewang Tashi, MD, discusses ​the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.